Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TAK
TAK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TAK News
Insilico Medicine Partners with Takeda for AI-Driven Drug Development
6d ago
seekingalpha
Biotech Sector Update: FDA and EU Approvals
Jun 26 2026
NASDAQ.COM
Takeda Appoints New CEO Julie Kim Amid Leadership Transition
Jun 24 2026
NASDAQ.COM
Takeda Completes Leadership Transition with New CEO Appointment
Jun 24 2026
seekingalpha
Takeda Appoints New President
Jun 24 2026
Yahoo Finance
Takeda Appoints Julie Kim as CEO Following Shareholder Vote
Jun 24 2026
Newsfilter
Takeda Canada Says Zasocitinib Shows Superiority to Deucravacitinib in Phase 3 Psoriasis Study
Jun 23 2026
Yahoo Finance
Takeda's Zasocitinib Shows Superiority in Psoriasis Study
Jun 23 2026
NASDAQ.COM
Denali Sells Rare Pediatric Disease Priority Review Voucher for $195 Million
Jun 19 2026
NASDAQ.COM
Takeda Reports New Data on Oveporexton for Type 1 Narcolepsy
Jun 16 2026
NASDAQ.COM
Takeda Unveils New Narcolepsy Drug Study Results
Jun 16 2026
NASDAQ.COM
Takeda Presents Oveporexton Study Results at SLEEP 2026
Jun 15 2026
Newsfilter
Takeda's Zasocitinib Outperforms Rival in Psoriasis Trial
Jun 11 2026
seekingalpha
Zasocitinib Shows Superiority in Psoriasis Study
Jun 11 2026
Newsfilter
Takeda's ENTYVIO Receives FDA Acceptance for Pediatric Use
Jun 10 2026
NASDAQ.COM
Takeda Seeks FDA Approval for ENTYVIO in Pediatric Patients
Jun 09 2026
Newsfilter
Show More News
